# Artesunate in Preemptive Treatment of Human Cytomegalovirus (CMV) in Stem Cell Transplant Recipients

> **NCT00284687** · PHASE3 · COMPLETED · sponsor: **Hadassah Medical Organization** · enrollment: 20 (estimated)

## Conditions studied

- Cytomegalovirus Infections

## Interventions

- **DRUG:** Artesunate

## Key facts

- **NCT ID:** NCT00284687
- **Lead sponsor:** Hadassah Medical Organization
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07
- **Primary completion:** 2010-03
- **Final completion:** 2010-03
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2010-06-10

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00284687

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00284687, "Artesunate in Preemptive Treatment of Human Cytomegalovirus (CMV) in Stem Cell Transplant Recipients". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00284687. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*